Your browser doesn't support javascript.
loading
Estimated cost-savings from optimizing use of inhaled medications for inpatients with obstructive lung disease.
Kondo, Ryuhei; Austin, Jennifer; Akel, Mary; Arora, Vineet M; Press, Valerie G.
Afiliação
  • Kondo R; Integral Corporation and The University of Chicago Booth School of Business, Chicago, IL, USA.
  • Austin J; Department of Pharmacy, The Johns Hopkins Medicine, Baltimore, MD, USA.
  • Akel M; Department of Medicine, Section of General Internal Medicine, University of Chicago, Chicago, IL, USA.
  • Arora VM; Department of Medicine, Section of General Internal Medicine, University of Chicago, Chicago, IL, USA.
  • Press VG; Department of Medicine, Section of General Internal Medicine, University of Chicago, Chicago, IL, USA.
J Asthma ; 60(2): 323-330, 2023 02.
Article em En | MEDLINE | ID: mdl-35230210
ABSTRACT

CONCLUSIONS:

Models representing transitions from all-nebulized to nebulizer-plus-MDI respiratory medications resulted in cost savings, largely from the reduction of labor cost of nebulizer administration with nebs-only treatment. Therefore, transitioning from nebs to MDIs can lead to cost savings and could allow greater opportunities for inhaler education.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Asma / Doença Pulmonar Obstrutiva Crônica Tipo de estudo: Health_economic_evaluation Limite: Humans Idioma: En Revista: J Asthma Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Asma / Doença Pulmonar Obstrutiva Crônica Tipo de estudo: Health_economic_evaluation Limite: Humans Idioma: En Revista: J Asthma Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos